UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel

Annals of oncology, 2016-03, Vol.27 (3), p.379-390

2016

Volltextzugriff (PDF)

Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges

Journal for immunotherapy of cancer, 2019-08, Vol.7 (1), p.205-13, Article 205

2019

Volltextzugriff (PDF)

Correction to: Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy

British journal of cancer, 2024-09, Vol.131 (5), p.954-954

2024

Volltextzugriff (PDF)

Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

Annals of oncology, 2021-02, Vol.32 (2), p.208-217

2021

Volltextzugriff (PDF)

Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review

Cancer treatment reviews, 2023-03, Vol.114, p.102511-102511, Article 102511

2023

Volltextzugriff (PDF)

Survival after neoadjuvant therapy with trastuzumab–lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials

ESMO open, 2022-04, Vol.7 (2), p.100433, Article 100433

2022

Volltextzugriff (PDF)

Antiinflammatory effects of natural tetranortriterpenoids isolated from Carapa guianensis Aublet on zymosan-induced arthritis in mice

Inflammation research, 2006-11, Vol.55 (11), p.457-464

2006

Volltextzugriff (PDF)

Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all?

Cancer treatment reviews, 2017-11, Vol.60, p.100-108

2017

Volltextzugriff (PDF)

9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio

Annals of oncology, 2018-10, Vol.29, p.viii705-viii705

2018

Volltextzugriff (PDF)

Liquid biopsy as tool to monitor and predict clinical benefit from chemotherapy (CT) and immunotherapy (IT) in advanced non-small cell lung cancer (aNSCLC): A prospective study

Annals of oncology, 2018-10, Vol.29, p.viii649-viii649

2018

Volltextzugriff (PDF)

Delay in progression of bone metastases in Breast cancer patients treated with intravenous pamidronate : Results from a Multinational randomized controlled trial

Journal of clinical oncology, 1996-09, Vol.14 (9), p.2552-2559

1996

Volltextzugriff (PDF)

Lipoxin A(4) attenuates zymosan-induced arthritis by modulating endothelin-1 and its effects

British journal of pharmacology, 2010-10, Vol.161 (4), p.911

2010

Volltextzugriff (PDF)

Non–Small-Cell Lung Cancer: Real-World Cost Consequence Analysis

European journal of public health, 2021-10, Vol.31 (Supplement_3)

2021

Volltextzugriff (PDF)

Tumor-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2+ breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the randomized shortHER trial

Annals of oncology, 2018-10, Vol.29, p.viii58-viii59

2018

Volltextzugriff (PDF)

Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: A multicenter phase II study

Lung cancer (Amsterdam, Netherlands), 2000-02, Vol.27 (2), p.75-80

2000

Volltextzugriff (PDF)

Lipoxin A4 attenuates zymosan‐induced arthritis by modulating endothelin‐1 and its effects

British journal of pharmacology, 2010-10, Vol.161 (4), p.911-924

2010

Volltextzugriff (PDF)

Lipoxin A 4 attenuates zymosan‐induced arthritis by modulating endothelin‐1 and its effects

British journal of pharmacology, 2010-10, Vol.161 (4), p.911-924

2010

Volltextzugriff (PDF)

77P Glycolytic marker monocarboxylate transporter 4 (MCT4) and outcome to bevacizumab (bev): An exploratory analysis in advanced non-small cell lung cancer (A-NSCLC)

Journal of thoracic oncology, 2016-04, Vol.11 (4), p.S88-S88

2016

Volltextzugriff (PDF)

211P Inflammatory cells characterization and localization in malignant pleural mesothelioma (MPM) tissue samples: Correlation with histologic subtype and prognosis

Journal of thoracic oncology, 2016-04, Vol.11 (4), p.S148-S148

2016

Volltextzugriff (PDF)

The curability of breast cancer and the treatment of advanced disease

European journal of nuclear medicine and molecular imaging, 2004-06, Vol.31 Suppl 1, p.S149-S161

2004

Volltextzugriff (PDF)

28P Different genetic profiling in lung adenocarcinoma of smokers with and without chronic obstructive pulmonary disease (COPD): An exploratory analysis by next generation sequencing (NGS)

Journal of thoracic oncology, 2016-04, Vol.11 (4), p.S67-S67

2016

Volltextzugriff (PDF)

Up date in the management of advanced ovarian carcinoma

Critical reviews in oncology/hematology, 1999-09, Vol.32 (1), p.49-58

1999

Volltextzugriff (PDF)

166P Non-small cell lung cancer (NSCLC) patients with rare or complex epidermal growth factor receptor (EGFR) mutations: A single institution series

Journal of thoracic oncology, 2016-04, Vol.11 (4), p.S130-S130

2016

Volltextzugriff (PDF)

Intraperitoneal chemotherapy in the management of patients with advanced epithelial ovarian cancer: a critical review of the literature

International journal of gynecological cancer, 2008-09, Vol.18 (5), p.943-953

2008

Volltextzugriff (PDF)

Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the “polmone toscano group” (POLTO)

Lung cancer (Amsterdam, Netherlands), 2005-04, Vol.48 (1), p.121-127

2005

Volltextzugriff (PDF)

1 – 25 von 1.742

Suche als RSS-Feed

Aktive Filter

ThemaMiddle Aged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.516)
Mit Volltextzugriff
(1.419)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(737)
Life Sciences & Biomedicine
(584)
Humans
(447)
Biological And Medical Sciences
(255)
Female
(234)
Medical Sciences
(207)
Physics
(188)
Male
(174)
Animals
(168)
High Energy Physics - Experiment
(129)
Oncology
(115)
Physical Sciences
(96)
Technology
(95)
Pharmacology. Drug Treatments
(93)
Adult
(74)
Pharmacology & Pharmacy
(68)
Fundamental And Applied Biological Sciences. Psychology
(65)
Endocrinology & Metabolism
(58)
Urology & Nephrology
(54)
Engineering
(52)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(17)
... seit 30 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel

Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges

Correction to: Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy

Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review

Survival after neoadjuvant therapy with trastuzumab–lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials

Antiinflammatory effects of natural tetranortriterpenoids isolated from Carapa guianensis Aublet on zymosan-induced arthritis in mice

Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all?

9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio

Liquid biopsy as tool to monitor and predict clinical benefit from chemotherapy (CT) and immunotherapy (IT) in advanced non-small cell lung cancer (aNSCLC): A prospective study

Delay in progression of bone metastases in Breast cancer patients treated with intravenous pamidronate : Results from a Multinational randomized controlled trial

Lipoxin A(4) attenuates zymosan-induced arthritis by modulating endothelin-1 and its effects

Non–Small-Cell Lung Cancer: Real-World Cost Consequence Analysis

Tumor-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2+ breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the randomized shortHER trial

Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: A multicenter phase II study

Lipoxin A4 attenuates zymosan‐induced arthritis by modulating endothelin‐1 and its effects

Lipoxin A 4 attenuates zymosan‐induced arthritis by modulating endothelin‐1 and its effects

77P Glycolytic marker monocarboxylate transporter 4 (MCT4) and outcome to bevacizumab (bev): An exploratory analysis in advanced non-small cell lung cancer (A-NSCLC)

211P Inflammatory cells characterization and localization in malignant pleural mesothelioma (MPM) tissue samples: Correlation with histologic subtype and prognosis

The curability of breast cancer and the treatment of advanced disease

28P Different genetic profiling in lung adenocarcinoma of smokers with and without chronic obstructive pulmonary disease (COPD): An exploratory analysis by next generation sequencing (NGS)

Up date in the management of advanced ovarian carcinoma

166P Non-small cell lung cancer (NSCLC) patients with rare or complex epidermal growth factor receptor (EGFR) mutations: A single institution series

Intraperitoneal chemotherapy in the management of patients with advanced epithelial ovarian cancer: a critical review of the literature

Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the “polmone toscano group” (POLTO)

Aktive Filter

Suchergebnisse filtern